VNRX: 3Q 2025 results reported Revenues & EPS above our expectations cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025.
Management's primary operational goal for 2025 is to secure multiple licensing agreements for human diagnostic applications. In September ...
152 Views
VNRX: During September
Primary operational goal for 2025 is to enter into multiple licensing agreements for human diagnostic applications, e.g. cancer & sepsis. In...
182 Views
VNRX: Management seeks to secure multiple licensing agreements in the human diagnostic space with the 1st one expected in 3Q 2025.
Primary operational goal for 2025 is to enter into multiple licensing agreements for human diagnostic applications, e.g. cancer & sepsis,...
246 Views
VolitionRx — Nu.Q advances in lung cancer management
Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need....
280 Views
VolitionRx — Building real-world Nu.Q NETs sepsis data
Volition continues to build data demonstrating that the Nu.Q® NETs H3.1 diagnostic platform is a potential breakthrough tool in sepsis management....
225 Views